Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma
NCT06296745Phase 2Recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in leptomeningeal metastasis (LM) and lung adenocarcinoma, sponsored by Guangzhou Medical University. Primary endpoints: Clinical response rate at 6 months and Neurological progression-free survival at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastasis (LM)lung adenocarcinoma
Beyond the preview
Go deeper on NCT06296745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296745.